Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
340
Trial Sponsor
Clinical Trial Start Date
2007
0Primary Completion Date
2011
0Study Completion Date
2011
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 10
Official Name
A Ph1 Open-Label,Dose-Escalation,Safety,PK & PD Study of CNF2024 as a Single-Agent Treatment in Subjects w/HER2- Adv Breast Cancer or in Combo w/Trastuzumab in Subjects w/HER2+ Advanced Breast Cancer0
Last Updated
June 8, 2012
0Allocation Type
Non-Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Other attributes
Intervention Treatment
CNF2024 + trastuzumab0
CNF20240
Study summary
The goal of this clinical research study is to study the drug CNF2024 as a single agent or in combination with trastuzumab in patients with advanced breast cancer and to: * find the highest dose of the drug CNF2024 as a single agent or in combination with trastuzumab that can be given safely * measure levels of CNF2024 as a single agent or in combination with trastuzumab in blood * determine if CNF2024 as a single agent or in combination with trastuzumab can stop breast cancer cells from growing
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
